Good news! Big Vision’s fully automated AI OCT has been successfully selected as one of the excellent domestically produced medical devices in the eighth batch!

Recently, the China Association for Medical Devices Industry completed the selection of products for the eighth batch of excellent domestically produced medical devices, among which, the Big Vision Optical Coherence Tomography (OCT) BV1000 was listed as an honor and selected into the eighth batch of “Excellent Domestically Produced Medical Device Product Catalog”.

The selection of the eighth batch of excellent domestically produced medical devices was organized by the China Association for Medical Devices Industry under the commission of the Planning, Development and Informationization Department of the National Health Commission. The selection process involved repeated verification of the technology and quality of the products, strict investigation of the use of the products by user units, and comprehensive evaluation of the application and enterprise situation. The “Excellent Domestically Produced Medical Device Product Catalog” was then formed, which is widely recognized by the government, hospitals, research institutions, enterprises, and media for its authority and objectivity.

Integration and innovation, opening a new future for domestically produced AI OCT

In the past 20 years, optical coherence tomography (OCT) has developed into an important tool in ophthalmology. It can achieve imaging of the retinal microstructure with high resolution and non-invasive methods, fundamentally changing the examination and diagnosis methods for ophthalmic patients and being widely used in ophthalmic clinics. The product BV1000 of Big Vision Medical Technology, which won the award this time, is a fully automated AI OCT that adopts advanced automatic control technology and integrates industry-leading OCT ophthalmic imaging AI algorithms. It is the world’s first software and hardware integrated AI OCT with completely independent intellectual property rights, bringing users and patients a new OCT examination experience.

With the deepening of the aging of our society, the incidence of fundus diseases such as age-related macular degeneration and diabetic retinopathy continues to rise, and the patient population is huge. It has become the leading cause of irreversible blindness. The “14th Five-Year” National Eye Health Plan released earlier this year proposed to promote early detection, diagnosis, and treatment of fundus diseases and glaucoma, improve the management mode of chronic eye disease patients, and promote the deep integration of emerging technologies such as big data, artificial intelligence, and 5G with ophthalmic services. The application of artificial intelligence in eye disease prevention, diagnosis, and follow-up to enhance early screening ability. Big Vision’s self-developed fully automated AI OCT BV1000 has solved the pain points of complex traditional OCT operations and high-level physician dependence on film reading. It has promoted the widespread use of OCT examination in ophthalmology at the county and grassroots level hospitals and provided affordable, accessible, and high-quality eye health services for the people. Since its launch, it has been applied in more than 100 hospitals and has received unanimous praise from doctors and patients, exploring a feasible AI path to solve the serious shortage of primary medical resources in ophthalmology in China.

Introduction of the selected product

BV1000

AI analysis

The fully automated AI OCT BV1000 integrates Big Vision’s leading OCT ophthalmic image AI algorithm, which can assist in the diagnosis of 16 major ophthalmic diseases, including macular edema, epiretinal membrane, vitreous opacity, choroidal neovascularization, and others. Patients can receive an assisted diagnostic report within 2 minutes after the examination is completed.

Easy to operate

The fully automated AI OCT BV1000 uses advanced algorithms to achieve rapid automatic positioning and focusing of the pupil, with full speech guidance. It takes an average of 2 minutes to complete a bilateral eye examination, and patients can complete the examination on their own. This greatly shortens the learning curve for hospital equipment operation and effectively addresses the shortage of primary medical resources in ophthalmology. At the same time, it significantly improves the efficiency of the examination.

Automatic file creation

The BV1000 examination results can be seamlessly connected to Big Vision’s Bright Lemon Eye Health Management Platform, which is built on a cloud platform, to establish and maintain eye health records that can be viewed and tracked for long-term management at any time.

Riding on the momentum and making further efforts

company focuses on the research and development, production, and sales of hardware and software systems for ophthalmic imaging artificial intelligence analysis and diagnosis. Its research and development capabilities are among the best in the world, and it is committed to becoming a global leader in ophthalmic artificial intelligence. Currently, it has received more than 70 innovative achievements and patents, and has won prestigious awards such as the first prize of the “Wu Wenjun Artificial Intelligence Technology Invention Award” and the second prize of the “Jiangsu Science and Technology Award” in the field of artificial intelligence.

Looking to the future, as a pioneer in ophthalmic imaging artificial intelligence analysis and diagnosis in China, Big Vision Medical Technology will continue to uphold the enterprise spirit of “dream, passion, and pragmatism”, forge ahead, and empower ophthalmic diagnosis and treatment with artificial intelligence, striving to become a global leader in ophthalmic artificial intelligence.